TrialCanadian journal of gastroenterology = Journal canadien de gastroenterologie2011

Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Remo Panaccione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.